Lv1
20 积分 2024-06-23 加入
Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
2天前
已完结
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
2天前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2天前
已完结
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
2天前
已完结
Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series
5个月前
已完结
Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis
5个月前
已完结
Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
5个月前
已完结
Effectiveness of thymectomy in juvenile myasthenia gravis and clinical characteristics associated with better outcomes
5个月前
已完结
Poor responses and adverse outcomes of myasthenia gravis after thymectomy: Predicting factors and immunological implications
5个月前
已完结
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report
5个月前
已完结
皖公网安备34019202002308
